Molecular Partners AG

MOLN • Biotechnology

$4.07

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$157.86M

Growth

-100.0%

Cash Flow

1/5

Trend

Volatile

Evidence

Manageable debt level · 0.05Healthy liquidity · 8.79Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 27, 2026, 12:16 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$4.07

Change0.00%

Shares Out38.79M

Market Cap$157.86M

52W Range3.53 - 5.36

Beta0.68

P/E-1.62

P/S0.00

P/B1.59

P/FCF-7.52

EV/Sales0.00

EV/EBITDA-2.65

Price$4.07

Change0.00%

Shares Out38.79M

Market Cap$157.86M

52W Range3.53 - 5.36

Beta0.68

P/E-1.62

P/S0.00

P/B1.59

P/FCF-7.52

EV/Sales0.00

EV/EBITDA-2.65

EV/FCF-3.02

Earnings Yield-15.42%

FCF Yield-13.30%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.05

Current Ratio8.79

Quick Ratio8.79

Revenue 5Y-100.00%

Target$21.00

Target Upside415.97%

Target Median$21.00

Target Range13.00 - 29.00

Volume1.73K

Avg Volume4.79K

EPS Surprise-0.07

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

27/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

90/100

Why this score▼

Manageable debt level · 0.05Healthy liquidity · 8.79Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

MOLN

Analyst sentiment

Based on 4 analyst votes · 2026-09-03

63/100

Neutral

Bullish

Hold

Bearish

Price Target

2026-08-27

Low

$13.00

Mean

$21.00

Median

$21.00

High

$29.00

Company Overview

IPO: 6/16/2021

Industry: Biotechnology

P/B i: 1.59

Debt / Equity i: 0.05

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.05

Current Ratio: 8.79

Quick Ratio: 8.79

Status: Good

🧾

No insider activity

No recent insider transactions available.

About the Company

Molecular Partners AG

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Source - link

Peers

ALEC APLT CRBP CRDF ELTX MIST NKTX PEPG RANI SAVA

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today reported corporate highlights and financial results for the first half of 2026.

GlobeNewsWire

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US.

GlobeNewsWire

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update across its pipeline of targeted alpha Radio-DARPin therapeutics (RDTs).

GlobeNewsWire

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and VILLEJUIF, France, July 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners”), and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the development of lead-212 (212Pb) based targeted alpha therapies (TAT), today announced that the first patients were dosed in the ongoing US multicenter Phase 1/2a study of drug candidate MP0712.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-12	-0.38	-0.45	-0.07
2026-03-12	-0.40011	-0.41	-0.00989
2025-10-30	-0.46	-0.41	0.05
2025-08-25	-0.53	-0.67	-0.14
2025-05-15	-0.42143	-0.5	-0.07857
2025-03-06	-0.44	-0.34	0.1
2024-10-31	-0.63	-0.57	0.06
2024-08-26	-1.26	-0.51	0.75
2024-03-14	-0.97	-0.68	0.29
2023-03-09	0.9	-0.56	-1.46
2022-10-27	-0.65592	-0.42	0.23592
2022-08-25	-0.65592	-0.15	0.50592